Work

A phase 1 trial of vandetanib (multikinase inhibitor of EGFR, VEGFR, and RET) in combination with everolimus (mTOR inhibitor) in patients with advanced malignancies.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.tps2639

Authors: Manojkumar Bupathi, Gerald Steven Falchook, David S. Hong, Ishwaria Mohan Subbiah, Sarina Anne Piha-Paul, Daniel D. Karp, Babita Saigal, Ralph Zinner, Jennifer J. Wheler, Apostolia Maria Tsimberidou, Siqing Fu, Steven I. Sherman, Funda Meric-Bernstam, Vivek Subbiah

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2613729599

Cites:

Cited by:

Related to: 10